Overview

A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma

Status:
Completed
Trial end date:
2016-09-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Alcon Research
Collaborator:
Novartis Institute for BioMedical Research
Treatments:
MGV354